Printer Friendly

TRADING IN EPITOPE HALTED PENDING CONCLUSION OF FDA BLOOD PRODUCTS ADVISORY COMMITTEE REVIEW OF PREMARKET APPROVAL APPLICATION

 BEAVERTON, Ore., Dec. 18 /PRNewswire/ -- Epitope Inc. (AMEX: EPT) today announced that it has requested the American Stock Exchange to halt the trading of its common shares pending the conclusion of a Food and Drug Administration (FDA) Blood Products Advisory Committee review meeting which is taking place at 1:45 p.m. EST today in Rockville, Md.
 The company expects to issue a statement today after the committee completes its review of the company's Premarket Approval application to market its OraSure(R) oral specimen collection device for use in HIV-1 screening in the United States.
 Epitope Inc. is an Oregon corporation utilizing biotechnology to develop diagnostic tests for AIDS and other indications and, through its agricultural unit, Agritope Inc., superior new plant varieties utilizing proprietary technology.
 -0- 12/18/92
 /CONTACT: Mary Hagen of Epitope, 503-641-6115; or Shari Annes of Annes Associates, 415-726-5400, for Epitope/
 (EPT)


CO: Epitope Inc.; American Stock Exchange; U.S. Food and Drug
 Administration ST: Oregon IN: MTC SU:


SW-LM -- SE008 -- 8264 12/18/92 13:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1992
Words:172
Previous Article:COURT DENIES REQUEST FOR PRELIMINARY PATENT INJUNCTION AGAINST HIGHLY PURIFIED FACTOR VIII:C PRODUCT
Next Article:GREAT WESTERN ANNOUNCES 1992 HOUSING AWARDS; ORLANDO HOUSING GROUP RECEIVES $50,000 GRANT
Topics:


Related Articles
TRADING OF U.S. BIOSCIENCE STOCK SUSPENDED PENDING CONCLUSION OF FDA COMMITTEE REVIEW
EPITOPE RECEIVES ORASURE UPDATE FROM FDA
FDA ADVISORY COMMITTEE RECOMMENDS PHASE III CLINICAL TRIAL OF HIV IMMUNOTHERAPEUTIC
DURAMED OPTIMISTIC AFTER FDA ADVISORY COMMITTEE MEETING ON CONJUGATED ESTROGENS
IMMUNEX DRUG RECOMMENDED BY FDA COMMITTEE FOR MOBILIZING AND TRANSPLANTING PERIPHERAL BLOOD STEM CELLS
FDA PANEL SCHEDULED TO REVIEW LEUKINE APPLICATION FOR NEW USE
Cygnus' GlucoWatch(R) Monitor to Be Reviewed by FDA Panel December 6, 1999.
FDA Advisory Committee Recommends Approval With Conditions for Cygnus' GlucoWatch(R) Automatic Glucose Monitor.
United Therapeutics Announces UT-15 NDA Will Not Require FDA Advisory Committee.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters